(12)	UK Patent Application	(19) GB (11) 2203040(13) A (43) Application published 12 Oct 1988
• •	Application No 8804888 Date of filing 1 Mar 1988	<ul> <li>(51) INT CL<sup>4</sup> <ul> <li>A61K 31/27 C07C 125/067</li> </ul> </li> <li>(52) Domestic classification (Edition J): <ul> <li>A5B 170 423 42Y 430 431 43Y 541 544 54Y 566 56Y 586 58Y 596 59Y 646 64Y 664 66Y HA LG C2C 220 227 22Y 29X 29Y 302 30Y 323 32Y 340 34Y 627 71Y KB U1S 2418 A5B C2C</li> </ul> </li> <li>(56) Documents cited EP A2 0193926</li> <li>(58) Field of search <ul> <li>A5B</li> <li>C2C</li> <li>Selected US specifications from IPC sub-class A61K</li> </ul> </li> </ul>
	Priority data (31) 3706914 (32) 4 Mar 1987 (33) DE	
(71)	Applicant Sandoz Ltd (Incorporated in Switzerland)	
(72)	35 Lichtstrasse, CH-4002 Basle, Switzerland Inventor Albert Enz	
(74)	Agent and/or Address for Service B A Yorke & Co Coomb House, 7 St John's Road, Isleworth, Middlesex, TW7 6NH	

(54) Phenyl carbamates

DOCKE

Δ

Δ

RM

ç.

(57) Compositions for systemic transdermal administration contain the compounds:

$$(-) \qquad \bigcirc \qquad \bigcirc \qquad \bigwedge_{\substack{p=c-m < R_1 \\ R_2 \\ m < R_4 \\ m < R_5 \\ m < R_4 \\ m < R_5 \\ m < R_4 \\ m < R_5 \\ m < R$$

where R, is --H, alkyl, cyclohexyl, allyl or benzyl

or

1'

 $R_2$  is -H, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub> or -C<sub>3</sub>H<sub>7</sub>  $R_1$  and  $R_2$  together with -N for a morpholino or piperidino group  $R_3$  is -H or alkyl  $R_4$  and  $R_5$  are alkyl, in their free base or acid addition salt form. The compositions particularly contain the novel  $R_4$  and  $R_5$  are alkyl, in their free base or acid addition salt form. The compositions particularly contain the novel compound (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate and are used to treat Alzheimer's disease, mania etc.

CASE 100-7041

#### PHENYL CARBAMATE

2


4

DOCKE

The present invention relates to a novel phenyl carbamate with anticholinesterase activity.

-1-

More particularly the invention relates to the (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate of formula I



in free base or acid addition salt form.

As can be seen from this formula, in free base form the sign of rotation of the compound of formula I is (-). However in acid addition salt form it may be (+) or (-). For instance the sign of rotation of the hydrogen tartrate is (+). The present invention covers the free base form as well as the acid addition salt forms, independently of their sign of rotation.

100-7041

The racemic mixture  $(\pm)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in form of its hydrochloride is known from the European patent application 193,926 where it is identified as RA<sub>7</sub> HCl.$ 

- 2 -

According to this disclosure the racemate in free base form is obtained by amidation of  $\alpha$ -m-hydroxyphenylethyldimethylamine with a corresponding carbamoyl halogenide. The resulting compound and its pharmacologically acceptable acid addition salts, which can be prepared from the free base in known manner, are disclosed as acetylcholinesterase inhibitors in the central nervous system.

It has now surprisingly been found that the (-)-enantiomer of formula I and its pharmacologically acceptable acid addition salts, hereinafter referred to as compounds according to the invention, exhibit a particularly marked and selective inhibition of the acetylcholinesterase.

These findings are unexpected, particularly since it is not believed that the dialkylaminoalkyl side chain, which contains the optically active centre, is mainly responsible for the acetylcholinesterase inhibiting activity of the phenyl carbamates.

The compounds according to the invention have never been specifically disclosed in the literature. The free base may be prepared from the racemate by separation of the enantiomers in accordance with known methods, e.g. using di-0,0'-p-toluyltartaric acid. The acid addition salts may be prepared from the free base in known manner. These include e.g. the hydrogen tartrate.

DOCKET

RM

The compounds according to the invention exhibit pharmacological activity as indicated in standard tests and are therefore useful as pharmaceuticals. They reach the central nervous system rapidly after s.c., i.p. or p.o. administration in rats. They exert a brain region-selective inhibition of acetylcholinesterase activity, hippocampal and cortical enzyme being more inhibited than acetylcholinesterase originating from striatum and pons/medulla. Furthermore they have a long duration of action.

- 3 -

The following results, for example, illustrate the pharmacological profile of the compounds according to the invention as compared to the corresponding isomers and racemates. Compound A is the compound of formula I in form of its hydrogen tartrate. Compound B is the optical isomer of said salt. C designates the racemic mixture of the compound of formula I and its optical isomer, in form of the hydrochloride.

#### In vitro assays

DOCKE.

# Electrically evoked <sup>3</sup>H-acetylcholine release from rat hippocampal slices

Electrically evoked  ${}^{3}$ H-acetylcholine ( ${}^{3}$ H-ACh) release from rat hippocampal slices is a functional <u>in vitro</u> model to investigate presynaptic muscarinic autoreceptor agonists and antagonists. This model can also be used as an indirect method to evaluate drugs which inhibit acetylcholinesterase (AChE). Inhibition of AChE activity leads to the accumulation of endogenous ACh which then interacts with presynaptic muscarinic autoreceptors and inhibits further release of  ${}^{3}$ H-ACh.

Rat hippocampal slices (Wistar strain, 180 - 200 g) are prepared by chopping into cross sections whole hippocampal slices at a distance of 0.3 mm with a McIlwain tissue chopper. Hippocampal slices obtained from 3 rats are incubated for 30 min. at 23 ° C in 6 ml Krebs-Ringer containing 0.1 uCi <sup>3</sup>H-choline and transferred into the superfusion chamber and superfused with Kreb's medium containing 10 µM hemicholinium-3 at a rate of 1.2 ml/min. at 30 ° C. Collection of 5 min. fractions of the superfusate begins after 60 min. of superfusion. Two periods of electrical stimulation (2 Hz rectangular pulses 2 msec, 10 mA, 2 min.) are applied after 70 min. ( $S_1$ ) and after 125 min. ( $S_2$ ) of superfusion. Test substances are added 30 min. before S<sub>2</sub> and are present in the superfusion medium until 145 min. of superfusion. At the end of the experiments the slices are solubilized in conc. formic acid and tritium content is determined in the superfusate and the solubilized slices. Tritium outflow is expressed as the fractional rate of tritium outflow per min. Electrically evoked tritium outflow is calculated by subtraction of the extrapolated basal tritium outflow from the total tritium outflow during the two min. of electrical stimulation and the following 13 min. and is expressed as percent of the tritium content at the beginning of the sample collection. Drug effects on stimulation evoked tritium outflow are expressed as the ratios  $S_2/S_1$ . All experiments are run in dublicates using a programmable 12 channel superfusion system. For the calculation a computer program is used.

In this test compound A inhibits electrically evoked  ${}^{3}H$ -ACh release from hippocampal slices by approximately 40 % (100  $\mu$ M) while racemate C (100  $\mu$ M) inhibits by approximately 25 %. The inhibitory effects of compound A and racemate C can be antagonized by atropine. These results are compatible with an AChE-inhibiting activity. Compound B is inactive in this model.

DOCKE.

- 4 -

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.